JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.